THERADIAG: management transactions · France · AMF

About THERADIAG

THERADIAG is a French company specialized in in vitro diagnostics and theranostics, meaning the combination of diagnosis and therapy to improve the follow-up of patients receiving biotherapies. Founded in 1986 by two former executives from Abbott France, the company initially focused on distributing in vitro diagnostic products, especially for autoimmune diseases, before progressively building its own proprietary product lines. Its development path has been shaped by a strong technological focus, notably through the adoption of Luminex-licensed Multiplex technology in 1999 and the subsequent launch of proprietary products and dedicated biotherapy-monitoring solutions. Today, THERADIAG’s business is organized around two complementary segments. The Diagnostics division provides reagents, instruments, controls and automation solutions for autoimmunity, allergy testing, microbiology and quality controls. The Theranostics activity relies on the TRACKER and i-Tracker ranges to measure the effectiveness of biologic therapies, mainly in autoimmune and chronic inflammatory conditions. According to the company, it is recognized as one of the leading niche players in autoimmunity and multiplexing, with a CE-marked product range and a strong position in biotherapy monitoring. From an industrial standpoint, THERADIAG is anchored in Croissy-Beaubourg, in the greater Paris area, where its headquarters and core operations are located. The company strengthened its R&D and production footprint by moving into a larger Marne-la-Vallée facility and later opened a site in Tours to support selected development and bioproduction initiatives. It relies on an international distributor network and states that it is present in more than 30 countries, with commercial reach across Europe, North America and Asia. Among recent milestones, the company expanded its monitoring test portfolio, particularly in biotherapies, and signed multiple distribution partnerships abroad. A major corporate event, however, was the merger-absorption of THERADIAG by BIOSYNEX, announced in late 2023 and completed on December 15, 2023. From an equity research perspective, THERADIAG therefore remains an important historical French medtech reference, but it ceased to exist as a standalone listed company following that transaction.